B Cell Lymphoma
From the Journals
Hedgehog signaling offers prognostic, therapeutic potential in CLL
Hedgehog signaling was associated with expression of GLI1, which could be a future therapeutic target.
From the Journals
BET inhibitors may target oncogene in ABC-like DLBCL
Preclinical research suggests TCF4 is an oncogene in ABC-like DLBCL and can be targeted via BET inhibition.
Conference Coverage
Bispecific CAR T-cell therapy yields complete responses in relapsed/refractory non-Hodgkin lymphomas
Development plans for anti-CD19, anti-CD20 therapy include phase 2 studies in mantle cell, CD19 CAR T cell relapsers.
Conference Coverage
5F9 plus rituximab take a bite out of drug-resistant NHL
AMSTERDAM – The combination thwarts a mechanism that non-Hodgkin lymphomas use to evade immune surveillance.
Conference Coverage
Obinutuzumab provides strong early responses in untreated MCL
AMSTERDAM – A minimal residual disease rate as high as 85% is “unprecedented” in this population of patients, the lead investigator of the LYMA-...
Conference Coverage
‘Encouraging’ responses seen with durvalumab plus R-CHOP in DLBCL
CHICAGO – Durvalumab plus R-CHOP induction produced a complete response rate of 54%.
Conference Coverage
R2 appears active in high-risk FL and MZL
CHICAGO – R2 produced responses in patients who were refractory to rituximab or both lenalidomide and rituximab at baseline.
Conference Coverage
Inhibitor produces high response rate in relapsed/refractory FL
CHICAGO – The PI3K-delta inhibitor ME-401, given with or without rituximab, produced an overall response rate of 80% in a phase 1b trial of...
News
FDA approves Polivy for DLBCL
The FDA approval is based on results of an open-label, multicenter clinical trial of 80 patients with DLBCL who had undergone at least one prior...
Conference Coverage
Chemo-free Smart Start regimen looks promising in poor-prognosis DLBCL
CHICAGO – There was “oohing and aahing” over results showing high response and survival rates for combined rituximab, lenalidomide, and ibrutinib...
Conference Coverage
Fixed-duration venetoclax-obinutuzumab superior to standard CLL therapy
CHICAGO – The immediately practice changing study offers a time-limited frontline option, one expert reported.